Dermatologic toxicities of targeted anticancer therapies targeted anticancer therapies

Journal of Supportive Oncology

Volumn 8, Issue 4, 2010, Pages 149-161

  Balagula, Yevgeniy ^a   Lacouture, Mario E ^b   Cotliar, Jonathan A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CETUXIMAB; CLINDAMYCIN; CLOBETASOL; DASATINIB; DEFOROLIMUS; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOCINONIDE; GEFITINIB; HYDROCORTISONE; IMATINIB; LAPATINIB; LIDOCAINE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; PLACEBO; PREDNISONE; SILVER NITRATE; SORAFENIB; STEROID; SUNITINIB; TAZAROTENE; TETRACYCLINE; UNINDEXED DRUG; UREA;

ACNE; ACTINIC KERATOSIS; ALOPECIA; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DEPIGMENTATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSESTHESIA; DYSURIA; GENITAL SYSTEM DISEASE; HAIR DISEASE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; KERATOACANTHOMA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOUTH ULCER; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; NAIL DISCOLORATION; NAIL DISEASE; NONHUMAN; NOSE ULCER; ONYCHOLYSIS; PAPULOPUSTULAR RASH; PARONYCHIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHOTOSENSITIVITY; PIGMENT DISORDER; PRURITUS; QUALITY OF LIFE; RADIATION DERMATITIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; SEBORRHEIC DERMATITIS LIKE RASH; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUBUNGUAL HEMORRHAGE; SUBUNGUAL SPLINTER HEMORRHAGE; TELANGIECTASIA; TRICHOMEGALY; XEROSIS;

ANTINEOPLASTIC AGENTS; EXANTHEMA; HUMANS; NAIL DISEASES; PIGMENTATION DISORDERS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES;

EID: 77956131018     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10:28-35. [19289369]
2. Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006;20:15-25. [16736979]
3. Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of EGFR inhibitor-induced dermatologic toxicities on quality of life. Cancer In press.
4. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812. [16990857]
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. [15269313]
6. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007;12:577-583. [17522246]
7. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20:851-855. [19826350]
8. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114:485-493. [18600445]
9. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144. [17655513]
10. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858. [17178882]
11. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. [16314617]
12. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-356. [15851793]
13. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16:557-566. [18274784]
14. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of handfoot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-1011. [18779536]
15. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18 suppl):1S-13S. [12235219]
16. Jost M, Kari C, Rodeck U. The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505-510. [11056418]
17. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137. [11252954]
18. Nanney LB, Stoscheck CM, King LE Jr, Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742-748. [1693937]
19. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26. [19229368]
20. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-326. [17141360]
21. Roé E, Garcia Muret MP, Marcuello E, Capdevila J, Pallarés C, Alomar A. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006;55:429-437. [16908348]
22. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119. [19452131]
23. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-621. [17522250]
24. Witherspoon JN, Wagner L, Rademaker A, West DP, Rosenbaum SE, Lacouture ME. Correlation of patient characteristics and NCICommon Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash. J Clin Oncol 2008;26:9559.
25. Wagner L, Lai SE, Aneja M, et al. Development of a functional assessment of sideeffects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): the FASTEGFRI. J Clin Oncol 2007;25[18S]:19532.
26. Abraham T, Rademaker A, Ortiz S, et al. Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. J Clin Oncol 2008;26:19094.
27. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-159. [18160805]
28. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-smallcell lung cancer. J Clin Oncol 2004;22:3238-3247. [15310767]
29. Perez-Soler R, Van Cutsem E. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park) 2007;21:10-16. [18154213]
30. U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.02_2009-09-15_QuickReference_5x7.pdf. Accessed May 22, 2010.
31. Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 2008;100:240-242. [18270340]
32. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-5396. [18048820]
33. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853. [18543329]
34. Mitchell EP, Lacouture M, Shearer H, et al. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009;27[18S]:CRA4027.
35. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in North Central Cancer Treatment Group study N0147. Oncology 2009;77:120-123.
36. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced nonsmall-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:2350-2357. [18467727]
37. Lai SE, Minnelly L, O'Keeffe P, et al. Influence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic. J Clin Oncol 2007;25(18S):9127.
38. Lacouture ME, Basti S, Patel J, Benson A 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-238. [16724647]
39. Scope A, Lieb JA, Dusza SW, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-620. [19646778]
40. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134. [17215530]
41. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. [17215529]
42. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin Genitourin Cancer 2009;7:11-19. [19213662]
43. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008;47:176-186. [18210295]
44. Schenone S, Bondavalli F, Botta M. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem 2007;14:2495-2516. [17979703]
45. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-123. [15654902]
46. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:1411-1416. [19228742]
47. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 2010;30:52-56. [20030473]
48. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955-1961. [18550575]
49. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents: the case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-134. [18188524]
50. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-596. [18070211]
51. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-892. [18645140]
52. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500. [15992698]
53. Huggins RH, Kuzel TM, Anderson RT, West DP, Lacouture ME. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). J Clin Oncol 2008;26:16122.
54. Sorafenib-Induced Hand-Foot Skin Reaction Treatment. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00667589?term=hfsr+tazarotene&rank=1. Accessed May 22, 2010.
55. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433. [16012181]
56. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43:845-851. [17289377]
57. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305. [19028406]
58. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-26. [15040473]
59. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003;4:366-369. [14599302]
60. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-1051. [19558553]
61. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-930. [18054825]
62. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116:210-215. [19862817]
63. Pongpudpunth M, Demierre MF, Goldberg LJ. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol 2009;36:1303-1307. [19519875]
64. Graves JE, Jones BF, Lind AC, Heffernan MP. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006;55:349-353. [16844529]
65. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002;147:598-601. [12207609]
66. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-670. [17010747]
67. Dueland S, Sauer T, Lund-Johansen F, Ostenstad B, Tveit KM. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003;42:345-346. [12899508]
68. Pascual JC, Banuls J, Belinchon I, Blanes M, Massuti B. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004;151:1111-1112. [15541102]
69. Bouché O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1711-1712. [15972283]
70. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-3462. [18612164]
71. Lacouture ME, Boerner SA, Lorusso PM. Non-rash skin toxicities associated with novel targeted therapies. Clin Lung Cancer 2006;8(suppl 1):S36-S42. [17239289]
72. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007;23:65-66. [17237698]
73. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-174. [15557594]
74. Kerob D, Dupuy A, Reygagne P, et al. Facial hypertrichosis induced by cetuximab, an anti-EGFR monoclonal antibody. Arch Dermatol 2006;142:1656-1657. [17179005]
75. Montagut C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 2005;23:5273-5275. [16051981]
76. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009;161:515-521. [19466958]
77. Mak KK, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem 2003;278:26120-26126. [12714603]
78. Philpott MP, Kealey T. Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles. J Invest Dermatol 1994;102:186-191. [8106747]
79. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995;14:5216-5223. [7489711]
80. Dasanu CA, Alexandrescu DT, Dutcher J. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 2007;100:328-330. [17396743]
81. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008;58:545-570. [18342708]
82. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. [16467544]
83. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28. [19897418]
84. Lacouture ME, Hwang C, Marymont MH, Patel J. Temporal dependence of the effect of radiation on erlotinib-induced skin rash. J Clin Oncol 2007;25:2140; author reply 2141. [17513824]
85. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007;357:514-515. [17671265]
86. Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008;3:5. [18226196]
87. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286-1299. [19170238]
88. Mitra SS, Simcock R. Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 2006;24:e28-e29. [16735697]
89. Bossi P, Liberatoscioli C, Bergamini C, et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 2007;18:601-602. [17074970]
90. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-e61. [19597016]
91. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-23. [19213663]
92. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006;31:783-785. [16824050]
93. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-5620. [18310500]
94. Shu KY, Kindler HL, Medenica M, Lacouture M. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 2006;154:191-192. [16403122]
95. Hammond-Thelin LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008;26:121-159, ix. [18023775]
96. Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to daily biotin supplementation. Cutis 1993;51:303-305. [8477615]
97. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010;13:29-43. [20167530]
98. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9:66-76. [19149483]
99. Pickering L, Rudman S, Ross PJ, Leslie MD. Targeted therapy in colorectal carcinoma: more than a theory. Colorectal Dis 2008;10:209-218; discussion 218-221. [18257846]
100. Bauer KA, Hammerman S, Rapoport B, Lacouture ME. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clin Colorectal Cancer 2008;7:309-314. [18794062]
101. Erbitux [package insert]. Princeton, NJ: Bristol-Myers Squibb; March 2010.
102. Vectibix [package insert]. Thousand Oaks, CA: Amgen Inc; May 2010.
103. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. [16014882]
104. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced nonsmall-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-869. [18281658]
105. Toi M, Iwata H, Fujiwara Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 2009;101:1676-1682. [19844234]
106. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512. [16636341]